NCT03197467View on ClinicalTrials.gov

Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 18, 2018

Primary Completion Date

October 30, 2021

Study Completion Date

May 5, 2023

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
DRUG

Pembrolizumab

Pembrolizumab at fixed dose: 200 mg q3w i.v. for 2 cycles

Trial Locations (1)

69126

Universitätsklinikum Heidelberg, Heidelberg

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

AIO-Studien-gGmbH

OTHER

NCT03197467 - Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter